title: Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
abstract: Diagnosis of low-grade diffuse gliomas based on morphology is highly subjective and, therefore, is often difficult, with significant intra- and interobserver variability. Here, we investigated WHO grade II diffuse astrocytomas, oligoastrocytomas and oligodendrogliomas for immunohistochemical expression of Olig2, measuring its labeling index (LI), and evaluated the significance of Olig2 LI in the histological and molecular classifications. The means of Olig2 LI in glioma cells were 43.7 % in diffuse astrocytomas, 59.3 % in oligoastrocytomas and 76.1 % in oligodendrogliomas. There was a statistically significant difference between all pairs of histological types. The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligodendrogliomas, was significantly higher than the means of those with TP53 mutation ± IDH1/2 mutation and IDH1/2 mutation only, the majority of which were diffuse astrocytomas (70.1 vs. 47.2 and 46.5 %, respectively). When categorized according to the classification of Jiao et al., Olig2 LI of I-CF gliomas (cases with IDH and one or more of CIC, FUBP1 or combined 1p/19q loss; mean 71.0 %) was significantly higher than that of I-A gliomas (cases with IDH and ATRX alterations; mean 45.3 %). These molecular classifications were reported to correlate well with clinical outcome. However, borderlines of Olig2 LI were broad and could not clearly distinguish genotypes in the molecular classifications. In conclusion, Olig2 LI cannot be taken as a complete surrogate marker for molecular genotype, but could possibly provide some ancillary information when molecular assay is not availabe.
authors.affiliation: Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Gunma, Maebashi, 371-8511, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Suzuki
authors.forename: Sumihito
authors.initials: S
authors.lastname: Nobusawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Natsume
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Young-Ho
authors.initials: YH
authors.lastname: Kim
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yokoo
authors.forename: Masaya
authors.initials: M
authors.lastname: Nagaishi
authors.forename: Hayato
authors.initials: H
authors.lastname: Ikota
authors.forename: Takuro
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Wakabayashi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Ohgaki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakazato
mesh_terms: D000293:Adolescent; D000328:Adult; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics / Q000378:metabolism*; D001932:Brain Neoplasms / Q000145:classification / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000145:classification* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D060787:Neoplasm Grading; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D000076104:Oligodendrocyte Transcription Factor 2; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D055815:Young Adult
chemical_list: D051792:Basic Helix-Loop-Helix Proteins; D007521:Isocitrate Dehydrogenase; D009419:Nerve Tissue Proteins; D000076104:Oligodendrocyte Transcription Factor 2; D016159:Tumor Suppressor Protein p53; C405708:OLIG2 protein, human; C495901:TP53 protein, human; C538784:IDH2 protein, human; C543588:IDH1 protein, human
references.citation: Neuron. 2001 Sep 13;31(5):791-807
references.pmid: 11567617
references.citation: Stem Cells. 2006 Apr;24(4):1001-10
references.pmid: 16253982
references.citation: Acta Neuropathol. 2012 Nov;124(5):615-25
references.pmid: 22886134
references.citation: J Pathol. 2012 Jan;226(1):7-16
references.pmid: 22072542
references.citation: Oncotarget. 2012 Oct;3(10):1194-203
references.pmid: 23104868
references.citation: Science. 2011 Jul 22;333(6041):425
references.pmid: 21719641
references.citation: Neuropathol Appl Neurobiol. 2005 Feb;31(1):62-9
references.pmid: 15634232
references.citation: Neuron. 2011 Mar 10;69(5):906-17
references.pmid: 21382551
references.citation: Nature. 2012 Jan 29;482(7384):226-31
references.pmid: 22286061
references.citation: Acta Neuropathol. 2012 Jun;123(6):853-60
references.pmid: 22588899
references.citation: Oncotarget. 2012 Jul;3(7):709-22
references.pmid: 22869205
references.citation: J Neurooncol. 2004 May;67(3):265-71
references.pmid: 15164981
references.citation: Curr Biol. 2002 Jul 9;12(13):1157-63
references.pmid: 12121626
references.citation: Brain Pathol. 2010 Jan;20(1):245-54
references.pmid: 19903171
references.citation: Acta Neuropathol. 2009 Oct;118(4):469-74
references.pmid: 19554337
references.citation: Nat Genet. 2013 Jun;45(6):602-12
references.pmid: 23583981
references.citation: Am J Pathol. 2004 May;164(5):1717-25
references.pmid: 15111318
references.citation: Cancer Cell. 2011 Mar 8;19(3):359-71
references.pmid: 21397859
references.citation: Acta Neuropathol. 2007 Aug;114(2):97-109
references.pmid: 17618441
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6
references.pmid: 11526205
references.citation: Acta Neuropathol. 2002 Mar;103(3):267-75
references.pmid: 11907807
references.citation: Science. 2011 Sep 9;333(6048):1453-5
references.pmid: 21817013
references.citation: Nature. 2011 Sep 11;478(7367):64-9
references.pmid: 21909114
references.citation: J Neuropathol Exp Neurol. 2004 May;63(5):499-509
references.pmid: 15198128
references.citation: Am J Pathol. 2010 Dec;177(6):2708-14
references.pmid: 21075857